Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas

Abstract

In summary, our findings demonstrate that the mTOR pathway is activated in PRLomas and that everolimus exhibits antiproliferative actions in vitro. We suggest that everolimus may be a novel therapeutic option for some aggressive PRL-secreting tumors unresponsive to conventional treatments.